Abstract: An aqueous pharmaceutical solution for use in the treatment of diseases of the central nervous system (CNS), comprises at least 5 mg/ml dissolved levodopa and has a pH in the range of 3.0 to 8.5. The solution is provided by mixing a) an aqueous stock solution comprising levodopa and having a pH of less than 2.8 at 25° C., and b) an aqueous buffering solution having a pH of at least 4.0 at 25° C. for increasing the pH of the stock solution. The aqueous pharmaceutical solution is administered to a subject suffering from a disease of the CNS shortly after mixing of the aqueous stock solution and the aqueous buffering solution. A kit for administration of the aqueous pharmaceutical solution includes a bag comprising two parts and a removable or perforable barrier between the two parts.

Abstract: The invention provides an aqueous pharmaceutical solution for use in the treatment of diseases of the central nervous system (CNS), the solution comprising at least 5 mg/ml dissolved levodopa, and having a pH in the range of 3.0 to 8.5. Said solution is provided by mixing a) an aqueous stock solution comprising levodopa, said stock solution having a pH of less than 2.8 at 25° C. and b) an aqueous buffering solution, for increasing the pH of said stock solution, said buffering solution having a pH of at least 4.0 at 25° C. The aqueous pharmaceutical solution is administered to a subject suffering from a disease of the central nervous system (CNS) shortly after mixing of the aqueous stock solution and the aqueous buffering solution. Furthermore, the invention provides a kit for administration of aqueous pharmaceutical solutions to subjects suffering from diseases of the central nervous system (CNS).

Abstract: The invention provides an aqueous pharmaceutical solution for use in the treatment of diseases of the central nervous system (CNS), the solution comprising at least 5 mg/ml dissolved levodopa, and having a pH in the range of 3.0 to 8.5. Said solution is provided by mixing a) au aqueous stock solution comprising levodopa, said stock solution having a of less than 2.8 at 25° C. and b) an aqueous buffering solution, for increasing the pH of said stock solution, said buffering solution having a pH of at least 4.0 at 25° C. The aqueous pharmaceutical solution is administered to a subject suffering from a disease of the central nervous system (CNS) shortly after mixing of the aqueous stock solution and the aqueous buffering solution. Furthermore, the invention provides a kit for administration of aqueous pharmaceutical solutions to subjects suffering from diseases of the central nervous system (CNS).

Abstract: The invention provides an aqueous pharmaceutical solution for use in the treatment of diseases of the central nervous system (CNS), the solution comprising at least 5 mg/ml dissolved levodopa, and having a pH in the range of 3.0 to 8.5. Said solution is provided by mixing a) au aqueous stock solution comprising levodopa, said stock solution having a of less than 2.8 at 25° C. and b) an aqueous buffering solution, for increasing the pH of said stock solution, said buffering solution having a pH of at least 4.0 at 25° C. The aqueous pharmaceutical solution is administered to a subject suffering from a disease of the central nervous system (CNS) shortly after mixing of the aqueous stock solution and the aqueous buffering solution. Furthermore, the invention provides a kit for administration of aqueous pharmaceutical solutions to subjects suffering from diseases of the central nervous system (CNS).

Abstract: The invention provides an aqueous pharmaceutical solution for use in the treatment of diseases of the central nervous system (CNS), the solution comprising at least 5 mg/ml dissolved levodopa, and having a pH in the range of 3.0 to 8.5. Said solution is provided by mixing a) an aqueous stock solution comprising levodopa, said stock solution having a pH of less than 2.8 at 25° C. and b) an aqueous buffering solution, for increasing the pH of said stock solution, said buffering solution having a pH of at least 4.0 at 25° C. The aqueous pharmaceutical solution is administered to a subject suffering from a disease of the central nervous system (CNS) shortly after mixing of the aqueous stock solution and the aqueous buffering solution. Furthermore, the invention provides a kit for administration of aqueous pharmaceutical solutions to subjects suffering from diseases of the central nervous system (CNS).

Abstract: A compound of Formula 1 wherein, X represents an alkyl, alkylene, alkenyl, alkenylene, alkynyl or alkynylene group, optionally having at least one substituent selected from the group of —OR1 and —NR1R2, or Y represents —OTBS, —OR1, —NR1R2; Z represents —OR3 or ?O; and R1, R2 and R3 each independently stand for H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, optionally in the form of enantiomers racemic mixtures, or pharmaceutically acceptable salts thereof, for use as a medicament, in particular for use in anti-viral cancer treatment in mammals and for use in treatment of benign or neoplastic genital Human Papilloma Virus associated diseases and for use in treatment of non-genital warts.

Abstract: This invention describes the production of a polymeric film, specifically a mix of two different lattices, in order to obtain a barrier layer in food packaging that reduces bacterial cell growth. Said reduction in bacterial growth is a result of choosing not only a surface with chemical properties to prevent bacterial growth, but also, and especially, controlling the nanostructure of the surface in order to prevent bacterial adhesion and so prevent bacterial film formation. This is done by using a mixture of two lattices and thermally annealing the surface as needed to such surface topography that bacterial growth is decreased. This invention addresses the need for an increased shelf-life of groceries in order to reduce spoilage losses, and thus waste. In addition, this invention supports the need to monitor the spoilage of packaged food so that less food is unnecessarily disposed of and on the other hand, so that spoiled food is not consumed by humans.

Abstract: A compound of Formula 1 wherein, X represents an alkyl, alkylene, alkenyl, alkenylene, alkynyl or alkynylene group, optionally having at least one substituent selected from the group of —OR1 and —NR1R2, or Y represents —OTBS, —OR1, —NR1R2; Z represents —OR3 or ?O; and R1, R2 and R3 each independently stand for H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, optionally in the form of enantiomers racemic mixtures, or pharmaceutically acceptable salts thereof, for use as a medicament, in particular for use in anti-viral cancer treatment in mammals and for use in treatment of benign or neoplastic genital Human Papilloma Virus associated diseases and for use in treatment of non-genital warts.